about
Leukotriene receptor antagonists as maintenance and intermittent therapy for episodic viral wheeze in childrenTargeted therapies to improve CFTR function in cystic fibrosisNontuberculous mycobacteria in gastrostomy fed patients with cystic fibrosis.β1-Integrin Accumulates in Cystic Fibrosis Luminal Airway Epithelial Membranes and Decreases Sphingosine, Promoting Bacterial InfectionsThe oral corticosteroid-sparing effect of omalizumab in children with severe asthma.Elevated paracellular glucose flux across cystic fibrosis airway epithelial monolayers is an important factor for Pseudomonas aeruginosa growthSuccessful outcome following pneumonectomy in a teenage boy with cystic fibrosis: a case report.Passive immunisation of preterm infants with palivizumab against RSV infection.Hyperglycaemia and Pseudomonas aeruginosa acidify cystic fibrosis airway surface liquid by elevating epithelial monocarboxylate transporter 2 dependent lactate-H+ secretion.Ivacaftor and symptoms of extra-oesophageal reflux in patients with cystic fibrosis and G551D mutationChildhood cough.The evidence for high flow nasal cannula devices in infants.Leukotriene receptor antagonists as maintenance or intermittent treatment in pre-school children with episodic viral wheeze.Airway surface liquid homeostasis in cystic fibrosis: pathophysiology and therapeutic targets.Ataluren in cystic fibrosis: development, clinical studies and where are we now?Microbiological profiles of sputum and gastric juice aspirates in Cystic Fibrosis patients.IL-22 exacerbates weight loss in a murine model of chronic pulmonary Pseudomonas aeruginosa infectionA novel culture medium for isolation of rapidly-growing mycobacteria from the sputum of patients with cystic fibrosis.CK2 is a key regulator of SLC4A2-mediated Cl-/HCO3- exchange in human airway epithelia.Bronchial epithelial cells cultured from clinically stable lung allograft patients promote the development of macrophages from monocytes rather than dendritic cells.Use of somatostatin analogues to treat chylothorax in a child with Generalised Lymphatic DysplasiaThe critical role of TAK1 in accentuated epithelial to mesenchymal transition in obliterative bronchiolitis after lung transplantation.Compliance with inhaled corticosteroids is important when considering adrenal suppression.A multifunctional bispecific antibody against Pseudomonas aeruginosa as a potential therapeutic strategy.Primary bronchial epithelial cell culture from explanted cystic fibrosis lungs.Bile acid aspiration in people with cystic fibrosis before and after lung transplantation.Hypertrophic cardiomyopathy and transposition of great arteries associated with maternal diabetes and presumed gestational diabetes.Strategies to screen for adrenal suppression in children with asthma: there is no consensus among UK centres.TNFα from classically activated macrophages accentuates epithelial to mesenchymal transition in obliterative bronchiolitis.Prostaglandin therapy for ductal patency: how long is too long?Growth recovery after withdrawal of inappropriate inhaled fluticasone proprionate.Should we use montelukast in wheezy children?Characterisation of eppin function: expression and activity in the lung.How to use nasal nitric oxide in a child with suspected primary ciliary dyskinesia.Endothelial cell damage in idiopathic pneumonia syndrome.Strategies to screen for adrenal suppression in children with asthma should take account of compliance with inhaled corticosteroids.Lymphoid bronchiolitis presenting at birth in an immunocompetent child: Chronic interstitial lung disease of unknown aetiology.Oesophageal foreign body presenting with stridor associated with feeding.Sphingolipids as targets for inhalation treatment of cystic fibrosis.NonTuberculous Mycobacteria infection and lung transplantation in cystic fibrosis: a worldwide survey of clinical practice.
P50
Q24186483-178FC006-FF54-4F1A-9F20-0B864B2E8D63Q26781441-402BE01B-93E7-4FBB-B851-C6D834C0E39AQ33594229-E066BD15-8FEC-49F0-B7D4-DB61BA7CAF93Q33811046-34005D9C-B0E3-48C3-9BCA-A8194C4CBA4EQ34280350-06BAAAFB-F0A7-408A-8DA9-A3CE250232F5Q35016923-D1FC934B-DA50-47FA-BEF0-584C97322C59Q36249408-455FAD8A-B4B1-461D-ACE5-24E00EF08239Q36291130-1A00DF9A-CB18-4120-AA58-ABE9C5983DD2Q37448936-0982763E-D194-4742-B276-AE8595C0EF9FQ37605093-7D82A769-B8E4-4FF4-A860-8904A5086F77Q37991232-48418578-270E-40C5-ACDF-224AA2C8581DQ38182774-75E005C6-00BB-4F32-805D-1C6127C7C80BQ38656184-0B004B34-D103-47EA-B3DC-3E06A593B97CQ38683678-3A508E91-20C1-4636-8FF3-BC7B972A1254Q39450041-2F2C8EA4-8235-4E3D-97B4-0FA6A3952B20Q39721947-F3D91633-2827-4E51-A56D-5055412BD458Q40626615-68FAAFCD-E436-4C97-9F55-B83E4D9E420DQ41206476-7D8D9E41-74EC-4E57-9266-D3A8A8DEF8D1Q41368424-27E4F283-320C-47C3-AB0F-4D04A6B4DC4FQ41819235-12582D38-0CB3-4AC5-AFF8-1562EE4B5271Q41944345-65D2C2FC-888F-48B1-95FC-29E6834367B8Q42183099-7FDCA9E0-8BAA-406C-9901-C50246E6EE40Q42724155-C1C989D2-9F69-46DC-B066-84DE394CD286Q43083370-A0A8FF3F-65D1-4A3E-912A-3111B7F83C8EQ43141760-FA74C7B4-505A-428A-B3AD-41F358A48FA6Q43148899-4774A19D-4ED3-4245-9347-3D792CE85E7BQ46385860-86861F20-DDFE-4167-88C9-BBEE8F789F7CQ46410609-848CDD15-BEB6-47BD-BC5E-6B5143F29E08Q46561167-24C20E4B-A88A-4678-ADFF-AE0AD1EB0928Q46585879-FF3C961E-3819-4527-9F7B-11B5A3AFF57DQ46791800-EFE77067-CA80-4240-9449-16E78DAF98C7Q47810283-CC9672DD-D815-4CFE-AB27-6EB8852B2E79Q47834171-06AF8203-BB80-4059-9F6C-67DEEFD58E21Q47894379-A3863DE8-2A42-4F73-86EF-687E91F27BCEQ48239374-147C8216-C7CC-4857-B6CE-760CC3757451Q48488506-17652447-CE69-4C1E-AA33-7DF14EFD0045Q51639454-F95D00BE-B7F3-4E39-8421-0388E5A90A6BQ54206955-89C3658E-D6EA-40D1-BC6E-2AC1C4223113Q54227489-5E981084-ADB9-4139-B687-FD41ACB20631Q55041894-1A5EE3D2-3329-4CCE-B6F6-FDE6781AAC3A
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Malcolm Brodlie
@ast
Malcolm Brodlie
@en
Malcolm Brodlie
@es
Malcolm Brodlie
@nl
Malcolm Brodlie
@sl
type
label
Malcolm Brodlie
@ast
Malcolm Brodlie
@en
Malcolm Brodlie
@es
Malcolm Brodlie
@nl
Malcolm Brodlie
@sl
prefLabel
Malcolm Brodlie
@ast
Malcolm Brodlie
@en
Malcolm Brodlie
@es
Malcolm Brodlie
@nl
Malcolm Brodlie
@sl
P106
P21
P31
P496
0000-0003-4591-8299
P569
2000-01-01T00:00:00Z